Abstract
Prion diseases belong to a group of fatal infectious diseases with no effective therapies available. Throughout the last 35 years, less than 50 different drugs have been tested in different experimental animal models without hopeful results. An important limitation when searching for new drugs is the existence of appropriate models of the disease. The three different possible origins of prion diseases require the existence of different animal models for testing anti-prion compounds. Wild type, over-expressing transgenic mice and other more sophisticated animal models have been used to evaluate a diversity of compounds which some of them were previously tested in different in vitro experimental models. The complexity of prion diseases will require more pre-screening studies, reliable sporadic (or spontaneous) animal models and accurate chemical modifications of the selected compounds before having an effective therapy against human prion diseases.
This review is intended to put on display the more relevant animal models that have been used in the search of new antiprion therapies and describe some possible procedures when handling chemical compounds presumed to have anti-prion activity prior to testing them in animal models.
Keywords: Anti-prion drug, Model, Prion diseases, TSE, Transgenic mouse, PMCA, Cell-free system, Cell culture.
Current Topics in Medicinal Chemistry
Title:Animal Models for Testing Anti-Prion Drugs
Volume: 13 Issue: 19
Author(s): Natalia Fernández-Borges, Saioa R. Elezgarai, Hasier Eraña and Joaquín Castilla
Affiliation:
Keywords: Anti-prion drug, Model, Prion diseases, TSE, Transgenic mouse, PMCA, Cell-free system, Cell culture.
Abstract: Prion diseases belong to a group of fatal infectious diseases with no effective therapies available. Throughout the last 35 years, less than 50 different drugs have been tested in different experimental animal models without hopeful results. An important limitation when searching for new drugs is the existence of appropriate models of the disease. The three different possible origins of prion diseases require the existence of different animal models for testing anti-prion compounds. Wild type, over-expressing transgenic mice and other more sophisticated animal models have been used to evaluate a diversity of compounds which some of them were previously tested in different in vitro experimental models. The complexity of prion diseases will require more pre-screening studies, reliable sporadic (or spontaneous) animal models and accurate chemical modifications of the selected compounds before having an effective therapy against human prion diseases.
This review is intended to put on display the more relevant animal models that have been used in the search of new antiprion therapies and describe some possible procedures when handling chemical compounds presumed to have anti-prion activity prior to testing them in animal models.
Export Options
About this article
Cite this article as:
Fernández-Borges Natalia, Elezgarai R. Saioa, Eraña Hasier and Castilla Joaquín, Animal Models for Testing Anti-Prion Drugs, Current Topics in Medicinal Chemistry 2013; 13(19) . https://dx.doi.org/10.2174/15680266113136660177
DOI https://dx.doi.org/10.2174/15680266113136660177 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Inhibition of Tau Aggregation in Cell Models of Tauopathy
Current Alzheimer Research Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Phenolic and Organic Acids from <i>Spondias pinnata</i> Fruits
The Natural Products Journal Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate
Current Drug Delivery Synthesis of Salinosporamide A and Its Analogs as 20S Proteasome Inhibitors and SAR Summarization
Current Topics in Medicinal Chemistry Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry From Surface to Nuclear Receptors: The Endocannabinoid Family Extends its Assets
Current Medicinal Chemistry Development of PET Probes for Cancer Imaging
Current Topics in Medicinal Chemistry Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Microtubules in Apoptosis Induction: Are They Necessary?
Current Cancer Drug Targets Synthetic Routes and Biological Activities of Benzofuran and its Derivatives: A Review
Letters in Organic Chemistry